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Abstract In silico screening was performed to search for bi-
nary solids in which a phenylpiperazine-derivative drug was
cocrystallized with a dicarboxylic acid. The phenylpiperazine
derivative could be any of 61 such drugs, while the dicarbox-
ylic acid could be any of nine such acids. The uniqueness of
this approach was that two criteria had to be fulfilled simulta-
neously, namely a high propensity for cocrystallization and a
sufficient solubility advantage. Using the mixing enthalpies of
selected pairs of crystal formers with high affinities for one
another permitted the classification of candidates with a high
probability of cocrystallization. Further modeling of the solu-
bility advantage allowed the identification of many binary
solids that potentially exhibit significantly enhanced solubility
in water. Based on the computed values for the mixing en-
thalpies and solubility advantage factors, it was concluded that
dicarboxylic acids are both excellent coformers for
cocrystallization with phenylpiperazines and very good solu-
bility enhancers; indeed, the use of dicarboxylic acids as
coformers would allow the degree of dissolution to be tuned
for many of the studied drugs. The observed similarities of the
cocrystallization landscapes of the studied drugs and excipi-
ents were also explored.
Keywords Cocrystals . Solubility advantage .Mixing
enthalpy . Dicarboxylic acids . Phenylpiperazine derivatives
Introduction
Most organic compounds—including those of pharmacologi-
cal interest—are poorly or very poorly soluble in water [1, 2],
which complicates attempts to administer drugs directly and to
make them bioavailable [3]. One way of overcoming this dif-
ficulty is to cocrystallize the active pharmaceutical ingredient
(API; i.e., the drug) with a more soluble excipient [4]; in other
words, cocrystallization can yield a solubility advantage.
Given that this requires a good understanding of how the
physicochemical properties of solids are altered by
cocrystallization, it is clear to see why materials science [5]
is playing an increasingly prominent role in drug develop-
ment. Indeed, there are numerous examples of the advantages
of drug cocrystallization, including improvements in the phar-
macodynamic characteristics of APIs [6, 7]. However, while
its advantageous effects on solubility [8], dissolution rate, and
the dose–response relationship [9] as well as the possibility of
synergistic effects caused by the cooperative action of several
active substances [10] are all good reasons for attempting API
cocrystallization [11], other physicochemical characteristics
of drugs can also be improved by cocrystallization [12, 13].
For instance, cocrystallization has been employed to lower
hygroscopicity [14, 15], increase physical or chemical stabil-
ity [16, 17], modulate [18] and maintain [19] color, improve
mechanical properties [14], control morphological character-
istics, reduce the diversity of active forms of the substance
[20], and to address issues relating to the patenting [21] of
new solid forms of drugs [22]. All of these are important
aspects of one of the last stages of drug development: the
formulation of the most convenient solid form [23].
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The wide variety of both active substances and coformers
available on the market suggests that there are a huge number
of possible combinations. However, not all substance pairs are
miscible in the solid state, and predicting whether a solid dis-
persion takes the a form of physical mixture or an intermolecular
compound is not a trivial task [24]. Moreover, successful
cocrystallization does not guarantee that the new formwill pres-
ent a solubility advantage. Therefore, many different methods
have been developed for the virtual screening of cocrystals of
active pharmaceutical ingredients and to predict the solubility of
cocrystals. In general, such screening methods can be divided
into two broad classes. The first group of methods, often termed
Bab initio^methods, directly model hypothetical solid structures
while taking all of the properties of the crystal lattice into ac-
count [25]. This is accompanied by advanced and usually time-
consuming quantum-chemical calculations, which consider
many hypothetical crystal structures with various forms of sym-
metry. Some of the newest implementations of this approach
have proven to be quite effective [26, 27]. The second group
of methods ignore the characteristics of the crystal structure and
focus on the properties of the interacting molecules derived
directly from the structure of each coformer [24]. From the
perspective of practicality [28], the first group of methods have
limited applicability to cocrystal screening. Much more approx-
imate methods often present surprisingly high efficiency despite
the simplicity of the models used. For example, the statistical
analysis of large populations of binary systems allows the clas-
sification of coformer properties that promote cocrystal forma-
tion [29, 30]. Furthermore, the role of intermolecular interac-
tions in the formation of supramolecular patterns [31, 32] in
single-component and multicomponent solids has been
established in the literature through the introduction of the term
Bsynthon^ [33]. Alternatively, some methods that consider the
electrostatic potential surface of the molecule have been used to
identify the most likely contacts between components [24, 34,
35]. In particular, comparing values of the excess enthalpy of
mixing (Hmix) of coformers under supercooled conditions
[36–38] has been found to be a very efficient way to screen
for APIs that have a propensity to cocrystallize [25, 39–41].
Indeed, it has become possible to use this particular methodol-
ogy [40] to rationalize the selection of pairs of coformers based
on similarities in their affinities and cocrystallization landscapes.
This approach takes into account linear relationships between
the mixing enthalpies of components. As has been shown [40]
for aromatic and heteroaromatic amides, the cocrystallization
affinities of a set of chemical systems toward a group of
coformers can be predicted after appropriate selection of a ref-
erence compound. This idea is in accordwith chemical intuition,
and can be very helpful when attempting to identify pairs with
high probabilities of cocrystallization.
The work reported in the present paper focused on
phenylpiperazine derivatives (PPDs), an important group of
drugs that exhibit a variety of pharmacological activities.
These compounds contain a phenylpiperazine skeleton formed
by joining piperazine to a benzenemoiety.Many representatives
of this class have been successively marketed as valuable drugs.
Probably the most well-known representative is itraconazole
[42], which was first synthesized in 1984 and is a triazole anti-
fungal agent. It has a very broad spectrum of activity against a
variety of infections. Another well-known compound is ketoco-
nazole [43], which is classified as both approved and investiga-
tional due to its broad spectrum of antifungal activities. It is used
for long periods at high doses, especially in immunosuppressed
patients, but also for the treatment of many systemic fungal
infections such as chronic mucocutaneous candidiasis, oral
thrush, blastomycosis, and paracoccidioidomycosis. However,
many other phenylpiperazine-derivative drugs have been devel-
oped; a list of the most important is provided in Table 1.
The rest of this paper is organized as follows. First, an
experimentally validated hypothesis regarding the transfer-
ability of cocrystallization landscapes is documented. Then,
work done to screen a set of phenylpiperazine derivatives for
good candidates for cocrystallization with dicarboxylic acids
is reported (note that none of the derivatives had been
cocrystallized previously). Finally, a subsequent investigation
of the solubility advantage of each cocrystal highlighted by
the screening process, based on in silico prediction, is
discussed. To the author’s best knowledge, this is the first
report of comprehensive screening involving the prediction
of both drug cocrystallization ability and the solubility advan-
tage of each new solid form identified.
Methods
The following coformers were considered in this work: oxalic
acid (0), malonic acid (1), succinic acid (2), glutaric acid (3),
adipic acid (4), pimelic acid (5), suberic acid (6), azelaic acid
(7), and sebacic acid (8), where each number in parentheses is
the number of methylene groups in the chemical formula, i.e.,
n in HCOO(CH2)nCOOH. All of these dicarboxylic acids
(DCAs) appear in the EAFUS (Everything Added to Food in
the United States) database [44] and the GRAS (Generally
Recognized As Safe) list [45]. The affinities of these excipi-
ents for the APIs listed in Table 1 were quantified based on the
estimated mixing enthalpy in the hypothetical supercooled
state under ambient conditions. Enthalpy values were comput-
ed using the COSMOtherm software [46], utilizing the
COSMO-RS (COnductor-like Screening MOdel for Real
Solvents) approach [47, 48]. The cocrystallization propensi-
ties were estimated based on the correspondence between the
miscibility in the solid state and that in liquids, as quantified
by the mixing enthalpy:
ΔHmix12 ¼ x1H112 þ x2H212− x1H11 þ x2H22
 
; ð1Þ
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where x denotes a mole fraction, superscripts indicate solvent
types, and subscripts indicate solutes. This means that the
excess enthalpy is obtained by subtracting the reference state
values characterizing the pure components from the sum of
the molar enthalpies of the components in the mixture.
Technically, three calculations are necessary in which each
of the pure components and the mixture are characterized by
molar enthalpy values. The advanced level defined by the
BP_TZVPD_FINE_C30_1601.ctd parameter set [46] was ap-
plied. The geometries of all compounds in both the gas and
Table 1 List of the most
important phenylpiperazine
derivatives considered in this
paper
No. Chemical name Activity Type CAS Codea
1 N-phenylpiperazine – 92-54-6
2 Antrafenine Anti-inflammatory Drug 55300-30-6 DB01419
3 Aripiprazole Antipsychotic Drug 129722-12-9 DB01238
4 Bifeprunox Antipsychotic Drug 350992-10-8 DB04888
5 Brexpiprazole Antipsychotic Drug 913611-97-9 DB09128
6 Cariprazine Antipsychotic Drug 839712-12-8 DB06016
7 Ciprofloxacin Antibiotic Drug 85721-33-1 DB00537
8 Dapiprazole Alpha blocker Drug 72822-12-9 DB00298
9 Dropropizine Antitussive Drug 17692-31-8 D07393
10 Elopiprazole Antipsychotic Drug 115464-77-2
11 Eltoprazine Serenic, antiaggressive Drug 98206-09-8
12 Etoperidone Antidepressant Drug 52942-31-1
13 Itraconazole Antifungal Drug 84625-61-6 DB01167
14 Ketoconazole Antifungal Drug 79156-75-5 DB01026
15 Levodropropizine Antitussive Drug 99291-25-5 D08119
16 Levofloxacin Antibiotic Drug 100986-85-4 DB01137
17 Lubazodone Antidepressant Drug 161178-07-0 DB09196
18 Mepiprazole Anxiolytic Drug 20326-12-9
19 Mianserin Antidepressant Drug 24219-97-4 DB06148
20 Moxifloxacin Antibacterial Drug 151096-09-2 DB00218
21 Naftopidil Antihypertensive Drug 57149-07-2
22 Nefazodone Antidepressant Drug 83366-66-9 DB01149
23 Niaprazine Hypnotic Drug 27367-90-4 D07333
24 Oxypertine Antipsychotic Drug 153-87-7 D01219
25 Posaconazole Antifungal Drug 171228-49-2 DB01263
26 Tioperidone Antipsychotic Drug 52618-67-4
27 Tolpiprazole Tranquillizer, anxiolytic Drug 20326-13-0
28 Trazodone Antidepressant Drug 19794-93-5 DB00656
29 Umespirone Antipsychotic Drug 107736-98-1
30 Urapidil Antihypertensive Drug 34661-75-1
31 Vesnarinone Cardiotonic Drug 81840-15-5
32 Acaprazine Anxiolytic Research 55485-20-6
33 Batoprazine Serenic, antiaggressive Research 105685-11-8
34 CHEMBL260870 Serotonergic Research
35 CHEMBL285066 Anxiolytic Research
36 CHEMBL534232 Serotonergic Research 193611-72-2
37 Enpiprazole Anxiolytic Research 31729-24-5
38 Ensaculin Nootropic Research
39 Flesinoxan Antidepressant Research 98206-10-1 D02568
40 Flibanserin Aphrodisiac Research 167933-07-5 D02577
41 Fluprazine Serenic Research 76716-60-4
42 Lorpiprazole Anxiolytic Research 108785-69-9
43 Naluzotan Antidepressant Research 740873-06-7
44 Naphthylpiperazine Serotonergic Research 57536-86-4
45 S-14506 Serotonergic Research 135722-25-7
46 S-14671 Serotonergic Research 135722-27-9
47 S-15535 Serotonergic Research 146998-34-7
48 SB-258585 Serotonergic Research 209480-63-7
49 SB-271046 Serotonergic Research CID5312149b
50 SB-357134 Serotonergic Research CID6918649b
51 SB-399885 Serotonergic Research 402713-80-8
52 Sonepiprazole Dopaminergic Research 170858-33-0
53 Vortioxetine Antidepressant Research 508233-74-7 D10184
54 WAY-100135 Serotonergic Research 133025-23-7
55 WAY-100635 Serotonergic Research 146714-97-8
56 Zolertine Antihypertensive Research 4004-94-8
57 1-(3-Chlorophenyl)piperazine Serotonergic Developed 6640-24-0
58 1-(4-Chlorophenyl)piperazine Serotonergic Developed 38212-33-8
59 2,3-Dichlorophenylpiperazine Serotonergic Developed 41202-77-1
60 Para-fluorophenylpiperazine Serotonergic Developed 2252-63-3
61 Trifluoromethylphenylpiperazine Serotonergic Developed 15532-75-9
a DB = DrgBank, D = KEGG
b PubChem ID
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condensed phases were optimized using the BP-RI/TZVP
scheme, which was followed by σ-profile computation by
means of the BP-RI/TZVPD approach in Turbomole v7.0
[49] interfaced with TmoleX 4.2 [50].
In the second part of this investigation, the solubility ad-
vantage was estimated by computing the following measure:




where Scc denotes the solubility (in mol/L) of the cocrystal and
SAPI (in mol/L) is the drug solubility. The cocrystal solubility
was computed via the salt solubility option in the COSMOtherm
program, neglecting the contributions arising from the Gibbs
free energy of fusion. When estimating API solubility, the iter-
ative procedure was applied, and a QSPR model implemented
in COSMOtherm was utilized forΔGfus estimation.
Results and discussion
This section is divided into three parts, each addressing one of
the major objectives of the work reported here. The main goal
was to screen for the most promising drug–excipient pairs that
not only had high probabilities of cocrystallization but also of-
fered acceptable solubility advantages. This two-condition
screening approach is very practical since it eliminates many
of the cases that are not interesting from a practical pharmaceu-
tical perspective. New solid forms of drugs are only useful if
they offer an advantage over the single-component formulation.
In order to successfully perform this final step, the newly
proposed methodology [25, 40] of screening via analogy was
validated and applied to the target group of drugs. The working
paradigm for cocrystal screening is that miscibility in the solid
state can be adequately predicted from the thermodynamics of
the miscibility of liquids in the metastable supercooled state
under ambient conditions. Unfortunately, as mentioned previ-
ously [25], detailed statistical analysis suggests that it is not
possible to distinguish cocrystals from simple binary eutectics
univocally. The number of misclassified cases heavily depends
on the selected threshold value of Hmix. Thus, an additional
condition was suggested [40], which takes advantage of simi-
larities in the cocrystallization landscapes of different substances
that belong to the same class of compounds. Thus, the similar-
ities of the cocrystallization landscapes of the nine dicarboxylic
acids are documented here, as are the similarities of the
cocrystallization landscapes of the phenylpiperazine derivatives.
Transferability of the cocrystallization landscapes
of DCAs
In the first step, the cocrystallization landscapes of the dicar-
boxylic acids were characterized by listing all known binary
solids that include these acids. This was done by searching
within the Cambridge Structural Database (CSD) [51] and in
the available literature [19, 52–59], and 374 cocrystals were
obtained, all of which are documented in Table S1 of the
BElectronic supplementary material^ (ESM). Each of these
bicomponent solids comprised one of the dicarboxylic acids
interacting with one of 175 diverse coformers such as amino
acids, drugs, amines, amides, phenols, other carboxylic acids,















(0)  [43] [0.921, 1.54]
(1)  [35] [0.968, 0.84]
(3)  [44] [0.988, 1.04]
(4)  [64] [0.978, 0.99]
(5)  [21] [0.979, 1.00]
(6)  [29] [0.965, 1.05]
(7)  [11] [0.957, 1.03]
(8)  [37] [0.928, 0.96]
experimentally confirmed
Fig. 1 Distributions of Hmix
values characterizing the affinities
of the 175 coformers for the nine
dicarboxylic acids (DCAs) with
respect to the corresponding
affinities of succinic acid (the
reference DCA). The DCAs are
labeled according to the number
of methylene groups in the
skeleton, i.e., by n in
HCOO(CH2)nCOOH: (0) oxalic
acid, (1) malonic acid, (2)
succinic acid, (3) glutaric acid, (4)
adipic acid, (5) pimelic acid, (6)
suberic acid, (7) azelaic acid, and
(8) sebacic acid. The legend lists
the number of experimentally
derived cocrystals as well as the
correlation coefficient R2 and
slope of the linear trend for each
acid
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Table 2 Examples of the transferability of cocrystallization landscapes characterizing the potential for the cocrystallization of various dicarboxylic
acids with a few representative phenylpiperazine drugs
API (0) (1) (2) (3) (4) (5) (6) (7) (8)
Isoniazid FADGEY FADGIC FADGOI FADGUO FADHAV SETRUG SETROA
+ (2:1) (1:2) (1:1) (1:2) (1:1) (2:1) + (2:1)
−2.61 −0.53 −0.89 −0.90 −0.79 −0.72 −0.73 −0.62 −0.53
Praziquantel TELCOE TELDEV TELDAR TELDIZ TELCAQ 54]
(1:1) (1:1) (1:1) (1:1) (1:2) (1:1) + + +
−3.31 −0.90 −1.30 −1.51 −1.42 −1.40 −1.55 −1.44 −1.29
Caffeine GANXUP GANYAW EXUQUJ CESKAN [55]
(1:2) (1:2) + (1:1) (1:1) + (1:1) + +
−2.47 −0.42 −0.63 −0.80 −0.69 −0.64 −0.73 −0.61 −0.45
Pyrazine GUDSUV GUDTAC VAXWAU GUDTOQ GUDVAE
(1:1) (1:1) (1:1) (1:1) (1:1) + + + +
−3.35 −0.92 −1.38 −1.45 −1.31 −1.29 −1.37 −1.27 −1.10
Carbamazepine MOXWUS MOXVUR XOBCIB MOXVOL MOXVEB
(1:1) (1:1) (0.5:1) (1:1) (0.5:1) + + + +
−1.48 −0.32 −0.48 −0.56 −0.52 −0.50 −0.54 −0.48 −0.43
Pyrazinamide SIHRAE LATTOR SIHQOR [17] [17]
+ (1:1) (0.5:1) (1:1) (1:1) + + + (1:1)
−2.25 −0.43 −0.70 −0.71 −0.60 −0.55 −0.55 −0.45 −0.34
Phenazine XAPMIK ZUPLEB WOQBOT WOQBUZ
(1:1) (2:1) (1:1) (2:1) + + + + +
−3.24 −0.71 −1.19 −1.43 −1.34 −1.28 −1.44 −1.30 −1.17
Urotropine MIPVEM IJETOG FITQII EKECOM
+ + + + (1:1) (1:1) + (1:1) (1:1)
−5.21 −2.61 −2.82 −2.99 −2.83 −2.78 −2.92 −2.78 −2.54
Theophylline XEJWUF XEJXAM XEJXIU
(1:2) (1:1) + (1:1) + + + + +
−1.99 −0.30 −0.47 −0.58 −0.48 −0.42 −0.48 −0.37 −0.26
Lamivudine VISWAX
+ – + – – (1:2) – – –
−1.24 −0.17 −0.21 −0.17 −0.14 −0.05 0.01 0.09 0.09
The codes FADGEY, FADGIC, etc. relate to the record for this cocrystal in the Cambridge Structural Database (CSD). The data given for each cocrystal
below the CSD code (if present; sometimes a relevant reference is cited instead, and sometimes there is no code nor reference for the cocrystal) are the
stoichiometry of the cocrystals (if known; otherwise a Bplus^ symbol is shown) and the computed value ofHmix (in kcal/mol). The numbers heading the














(0)  [43] [0.896, 1.50] (1)  [35] [0.953, 0.89]
(3)  [44] [0.993, 1.04] (4)  [64] [0.989, 0.99]
(5)  [21] [0.994, 1.00] (6)  [29] [0.983, 1.04]
(7)  [11] [0.987, 0.99] (8)  [37] [0.965, 0.89]
Fig. 2 Distribution of Hmix
values characterizing the affinities
of 61 phenylpiperazine analogs
for nine dicarboxylic acids. The
notation is the same as that
adopted in Fig. 1
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stoichiometry of the intermolecular complex. The majority
(56%) of them exhibited a 1:1 ratio of components. Another
24% of the structures were characterized by a conformer:DCA
stoichiometry of 2:1. A stoichiometry of 1:0.5 was found in
10% of the cocrystals. Other stoichiometries such as 0.5:1,
1:1.5, 2:3, and 3:1 were also observed, but they were quite
rare. As mentioned in the BMethods^ section, the affinities of
the coformers were quantified based on values of the mixing
enthalpy in the hypothetical supercooled metastable state un-
der ambient conditions. Hence, Hmix values were computed
for all 1575 binary mixtures defined as all possible combina-
tions of the considered dicarboxylic acids with the compounds
in the list of 175 coformers. The resulting values were plotted
as a function of the Hmix of the selected reference compound.
Succinic acid was chosen for this purpose as it is involved in
as many as 90 cocrystals—no other dicarboxylic acid was
used as frequently for binary solid synthesis. The resulting
relationships (see Fig. 1) show interesting trends. The affini-
ties of the dicarboxylic acids for of the considered coformers
are quite similar to those characterizing succinic acid. Note
that Fig. 1 presents two kinds of systems. The black and gray
symbols are the possible combinations of coformers, includ-
ing many that have not yet been synthesized. Overlaid on
those data points are red symbols representing experimentally
obtained cocrystals. The trends in both sets of data plotted
suggest that the Hmix value distributions are similar for all
DCAs except oxalic acid (this is understandable, as this com-
pound is the most acidic of all the excipients studied here, and
in many cases it is able to enforce salt formation with proton-
accepting coformers). The main conclusion drawn from Fig. 1
is that knowledge of the cocrystallization abilities of succinic
acid allows us to infer the cocrystallization characteristics of
other DCAs—a conclusion supported by the relatively high
correlation coefficients observed (R2 > 0.9). This behavior has
already been reported [40] for aromatic amides, when it was
termed Bthe similarity of cocrystallization landscapes.^ It ap-
pears that such behavior is exhibited many families of com-
pounds. It is worth noting that this analogy is not based on a
simple representation of the formal structure. For example,
one of the strongest homosynthon systems is formed between
two carboxylic groups. This structure is classified in graph
theory as R2
2(8), and is stabilized by two very strong hydrogen
bonds. The contributions of these hydrogen bonds to the total
stabilization energy of the crystal lattice can significantly ex-
ceed 50%; e.g., in crystals of aromatic carboxylic acids, the
synthon stabilization energy exceeds the sum of the other
kinds of intermolecular interactions that occur in the crystal
lattice [60–62]. It is true that increasing the pressure can affect
all types of interactions in a nonmonotonic manner [62], but
the synthon stabilization energy still provides the dominant
share of the total energy of the crystal. It is worth mentioning
that linear trends [41, 63] between the stabilization energies of
homo- and heterosynthons and the values of the Hammett
constants σ describing the electrophilic and nucleophilic char-
acter of the substituents have been observed. However, the
expectation that a similar relationship will also be observed
for Hmix as a function of σ cannot be justified, as no such
relationships have been found. Thus, while there is a simple
relationship between the Hammett constants and the synthon
stabilization energy [39], there is no similar relationship for
Hmix. This suggests that substituent effects make a nontrivial
contribution to the total affinity of the coformers and it is not
possible to infer the cocrystallization probability directly from
the synthon energetics. This is clearly demonstrated by the
statistical analysis of existing cocrystals, which show that
Table 3 Cocrystal screening resul ts for three se lected
phenylpiperazines
Ketoconazole Dapiprazole Itraconazole
(0) −5.31 −5.31 −3.31
(1) −2.50 −2.34 −0.75
(2) −2.91a −2.82 −1.24b
(3) −3.09 −3.05 −1.43
(4) −2.97c −2.92 −1.34
(5) −2.92 −2.85 −1.31
(6) −3.07 −3.04 −1.44
(7) −2.92 −2.87 −1.32
(8) −2.73 −2.65 −1.16




y = 1.51x - 3.10
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Fig. 3 Correlations between the experimentally determined and the
estimated solubility advantage values in water for three sets of data: A
carbamazepine with saccharin, nicotinamide, succinic acid, malonic acid,
oxalic acid, salicylic acid, or glutaric acid [6]; B theophylline with
nicotinamide or salicylic acid [70]; C caffeine with malonic acid,
glutaric acid, maleic acid, salicylic acid, or 1-hydroxy-2-naphthoic acid
[71]
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the formation of heterosynthon patterns is much preferred to
the formation of homosynthon patterns [64, 65]. For example,
a homosynthon formed from two carboxyl groups is far less
common than a heterosynthon generated from amide and car-
boxyl groups, despite the fact that the energy of a pair of
carboxyl groups is generally a few to several kcal/mol higher
than the energy of the amide and carboxyl pair [39, 62, 63]. In
this context, while the linear trends observed in Fig. 1 corre-
late well with chemical intuition, they are not a trivial repre-
sentation of the synthon energetics. This is also supported by
the lack of simple rules governing cocrystallization within
such a coherent class of compounds as aromatic carboxylic
acids—not every pair of aromatic acids forms an intermolec-
ular complex in the solid state, even though the stabilization
energies of all such pairs are actually very similar [39, 41].
Admittedly, there have been suggestions of a correspondence
between Hammett constant values and the cocrystallization
abilities of two aromatic acids [66, 67], but such a relationship
is only qualitative and not suitable for general cocrystal
prognostics.
The predictive potential of the proposed analysis based
on similarity can be demonstrated by inspecting particular
cases. Table 2 presents a small portion of this dataset, which
is included in its extended form in the ESM (Table S1). For
example, seven cocrystals of isoniazid with DCAs are
known. All of the acids show very strong affinity for this
antibiotic which is used for the prevention and treatment of
tuberculosis [68]. Therefore, it is very probable that it will
also cocrystallize with oxalic and azelaic acids. Also,
praziquantel (used as an anthelmintic agent for treating tape-
worm and fluke infections [69]) will probably cocrystallize
with suberic, azelaic, and sebacic acids. Using the contents
of Table 2 (and the full dataset provided in the ESM), it is
very easy to direct the synthesis of new solid forms. Note
that not all of the drugs considered here will form cocrystals
with dicarboxylic acids; for example, the affinities of almost
all of the DCAs for paracetamol, stanozolol, etravirine, and
cholesterin are so low that only oxalic acid forms cocrystals
with those drugs. Also, this affinity-based approach does not
always work. For instance, lamivudine—an antiretroviral
medication that is used to prevent and treat HIV/AIDS—
can be cocrystallized with pimelic acid (vis wax) despite
the fact that the affinity of lamivudine toward DCAs is so
low that its Hmix values are not sufficiently predictive. A
statistical analysis [25] suggested that the precision with
which pairs that form cocrystals can be distinguished from






















Fig. 4 Experimental water solubilities [72] of dicarboxylic acids.
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6 10 36 39 55 18 47 45 46
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dicarboxylic acids. The PPDs are
labeled in the same manner as in
Table 1
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Cocrystallization landscapes for phenylpiperazine
derivatives
There are only a few known cocrystals of PPDs with dicar-
boxylic acids. Indeed, succinic acid is involved in only two
cocrystals. One is formed with ketoconazole and the second
with itraconazole. The corresponding structures were deposit-
ed in the CSD under the codes YINWEZ and IKEQEU, re-
spectively. Also, adipic acid was successfully cocrystallized
with ketoconazole (YINWID). The other drugs presented in
Table 1 have not been studied experimentally in terms of their
cocrystallization potential. Thus, the results of the in silico
screening presented in Fig. 2 are the only collection of poten-
tial cocrystals of phenylpiperazine drugs. Inspection of the
plots suggests that many PPDs have high potential to
cocrystallize with DCAs, and many binary solids could be
synthesized. Hence, dicarboxylic acids are good choices for
cocrystallization agents with phenylpiperazine derivatives, as
the values of Hmix indicate strong affinities between such
coformers in the majority of cases. Furthermore, many of the
PPDs present the same mixing enthalpy distributions.
However, not all PPDs would be expected to cocrystallize
with DCAs. For example, the probability of successfully
cocrystallizing an antipsychotic agent such as bifeprunox with
DAs (except for oxalic acid) is low. However, such cases are
quite rare: among the 549 binary systems formed between 9
DCAs and 61 PPDs, only 25 do not fulfill the miscibility
criterion (Hmix < −0.17 [25]). Some results of the cocrystal
screening performed in this work for three selected PPDs are
collected in Table 3. The provided Hmix values strongly sug-
gest that all of the DCAs are able to form intermolecular com-
plexes with all of these drugs. As expected, the highest affin-
ities are obtained for oxalic acid, but even the least acidic
coformer (8) would be expected to be miscible in the solid
state with these PPDs. The full list of results from the in silico
screening performed here is provided in Table S2 of the ESM.
Potential solubility advantage of the cocrystallization
of PPDs with DCAs
While knowledge of the cocrystallization probabilities of a
series of PPDs is useful and interesting, it is not sufficient on
its own. The synthesis of new binary solids of all APIs and
drugs is a tedious and impractical path to generating new drug
formulat ions . Since the solubi l i ty advantage of
cocrystallization is very important, it is both necessary and
interesting to predict the potential benefits of synthesizing
new solid phases. This is why the screening process was also
extended to include this important feature of new supramolec-
ular systems of PPDs with DCAs. Since predicting the solu-
bilities of drug-like substances is not a trivial task, and esti-
mating cocrystal solubilities is even more problematic, it
would be useful to perform some preliminary tests of the
effectiveness of theoretical analysis. Thus, before actually
screening for solubility advantage, it is necessary to validate
this screening process using experimental data. In this work,
an approach involving the estimation of the solubility advan-
tage index was used, as described in the BMethods^ section
(see Eq. 2). Figure 3 presents plots of the experimentally mea-
sured solubility advantage for three sets of cocrystals in aque-
ous solution. Although the computed cocrystal and drug sol-
ubilities exhibit significant discrepancies from the available
experimental data in terms of absolute values, the computed
and experimental data do present similar trends. Thus, the
computed values do appear to be useful despite the fact that
they generally offer only a qualitative description of solubility
trends. The trends presented in Fig. 3 indicate that higher
predicted solubility advantage factors (SAest) are associated
with higher experimentally observed increases in solubility
after successful cocrystallization (SAexp). This qualitative
trend could prove very useful when attempting to direct the
synthesis of new cocrystals for further experimental verifica-
tion. Thus, as a rule of thumb, it was assumed in this work that
a sufficient solubility advantage can be expected if SAest > 4,
since this led to a significant gain in cocrystal water solubility
(SAexp > 1).
The utilization of dicarboxylic acids as potential solubility
enhancers can be justified by the diversity of their water sol-
ubilities. Based on the data provided in Fig. 4, it is possible to
divide DCAs into three classes. The first comprises the most
soluble compounds (including oxalic, malonic, and glutaric
acids), for which logS is positive at 25 °C. Modest solubility
is expected with succinic, adipic, and pimelic acids, for which
logS is negative but higher than −1. The other DCAs can be
considered to exhibit low solubilities, with logS being less
than −1. This high diversity of DCA solubilities in water is
actually rather fortunate, as it offers the potential to tune the
solubilities of the resulting binary solids within a wide possi-
ble solubility range. Unfortunately, there are no experimental
data on the solubilities of either PPDs or their cocrystals, so
theoretically derived values are the only data available. As
expected, the predicted values of logS for the PPDs suggest
that their water solubilities are very poor. For example, the
most water soluble of the PPD drugs ciprofloxacin and
fluprazine are still only barely soluble in water, since their
estimated logS values are −4.4 and −4.3, respectively. The
other phenypiperazine derivatives are even less soluble, and
the least soluble (tioperidone and antrafenine) are character-
ized by ultralow values of logS = −12.2 and −11.6, respective-
ly. These data confirm that it is worth studying the
cocrystallization of PPDs as a means to increase their bioavail-
ability. The computed solubility advantage factors suggest that
DCAs are potentially important water-solubility enhancers for
the PPD cocrystals considered here. In Fig. 5, the data fulfill-
ing SAest > 4 are plotted for intermolecular 1:1 complexes of
PPDs with the nine dicarboxylic acids. 2:1 and 1:2 complexes
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were also considered, but those data did not change the gen-
eral conclusions of the plot focusing on the 1:1 complexes.
According to chemical intuition, the solubility of a cocrystal
will depend on the characteristics of the dicarboxylic acid
present. Indeed, a monotonic decrease in solubility advantage
factors was observed to occur as the number of methylene
groups in the DCA skeleton increased. The highest solubility
gain was obtained for tioperidone (26). A positive effect of
cocrystallization on water solubility can also be expected for
many other PPDs, although not all—the solubility gain may
be negligible in some cases. However, the data shown in Fig. 5
suggest that 45 of them are worth invest igat ing
experimentally.
Conclusions
The in silico screening of both cocrystallization propensity
and solubility advantage performed in the present work ap-
pears to provide valuable information enabling the rational
planning of experiments. Based on these data, the synthesis
of new solid forms of phenylpiperazine-derivative drugs can
be effectively directed to maximize the pharmaceutically rel-
evant benefits of those drugs. The proposed combined screen-
ing approach not only highlights pairs of coformers with high
probabilities of cocrystallization but it also enables binary
solids that will not provide a sufficient improvement in water
solubility over that of the drug itself to be excluded. It is worth
mentioning that due to a lack of Gibbs free energy of fusion
values for the cocrystals, it is impossible to compute the ab-
solute values of the cocrystal solubilities. This can be over-
come by making use of some experimentally measured solu-
bilities of some training cocrystals. Due to the existence of
linear relationships between estimated solubilities and exper-
imental solubility advantage values, in silico screening can be
a very valuable tool when planning new experiments.
Unfortunately, this did not apply to the phenylpiperazine
drugs studied here, as the relevant experimental data are not
available. However, even in such cases, developing a theoret-
ical model is a goodway to obtain very pragmatic guidance, as
the model can yield a list of coformers with both the highest
probabilities of cocrystallization and sufficient solubility ad-
vantage values. An arbitrary threshold is applied to guide
coformer selection in such models, rather than general rules
relating to the physical properties of the studied cocrystals.
This categorization criterion can easily be tailored to meet
the requirements of a specific drug after obtaining solubility
measurements for some representative cases. Hence, even
though the performed computations are qualitative assess-
ments, the rational reduction of potential candidates for
cocrystallization is a valuable aid to the development of new
forms of the drugs studied here. However, each step of the
proposed procedure should be refined further. In particular,
the proposed methodology for selecting coformers based on
similar affinities rather than trivial synthon-reflected charac-
teristics may be especially important, particularly when Hmix
has low predictive power. It is obvious that it is not possible to
use the mixing enthalpy to explain the cocrystallization of a
system that contains very similar compounds and has
Hmix > −0.17 kcal/mol, yet such systems do exist. In those
cases, however, observed linear trends with respect to a select-
ed reference compound can enhance the applicability of mis-
cibility data. In silico screening using a combination of these
two criteria appears to provide valuable information enabling
the rational planning and direction of experimental searches
for new solid forms of active pharmaceutical ingredients.
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